{"entity":{"id":"adaptive-biotechnologies","kind":"company","name":"Adaptive Biotechnologies","aka":[],"tldr":"Adaptive Biotechnologies makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in ALL, myeloma, and CLL.","summary":"Adaptive Biotechnologies, based in Seattle and listed as ADPT, makes clonoSEQ, the FDA-cleared sequencing test that finds one leukaemia cell in a million and now guides treatment in acute lymphoblastic leukaemia, myeloma and chronic lymphocytic leukaemia. clonoSEQ sequences IGH, IGK, IGL and T-cell receptor clonotypes and was the first FDA-cleared next-generation sequencing test for measurable residual disease, in 2018 for ALL and myeloma and in 2020 for CLL; it serves as the MRD endpoint in trials and in routine practice, and the company also runs the T-Detect immune medicine business. OnCo links it to NGS-based MRD testing, to the bottleneck of dormant cells and minimal residual disease, and to ideas on reference materials for residual disease tests. Whether MRD can become a regulatory endpoint for approval is the open question. clonoSEQ has its own page.","asOf":"2026-09-07","links":[{"label":"Official website","url":"https://www.adaptivebiotech.com"}],"tags":[],"related":[],"cancers":["all-leukemia","multiple-myeloma","cll"],"sections":["diagnostics"],"technologies":["ngs-mrd-clonoseq","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"diagnostics","website":"https://www.adaptivebiotech.com","ticker":"ADPT","investors":[],"funding":[]},"route":"/companies/adaptive-biotechnologies/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"ngs-mrd-clonoseq","kind":"technology","name":"NGS-based MRD (clonoSEQ and molecular MRD)","route":"/technologies/ngs-mrd-clonoseq/"}],"bottleneck":[{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/"}],"idea":[{"id":"idea-bio2-mrd-reference-standards","kind":"idea","name":"Reference materials and open proficiency testing for residual disease tests","route":"/ideas/idea-bio2-mrd-reference-standards/"},{"id":"idea-bio2-tcr-repertoire-early-readout","kind":"idea","name":"Watch the immune system's response in the blood three weeks in","route":"/ideas/idea-bio2-tcr-repertoire-early-readout/"}],"drug":[{"id":"clonoseq","kind":"drug","name":"clonoSEQ","route":"/drugs/clonoseq/"}]}}